自体骨髓间充质干细胞回输治疗脑卒中30例

Reinfusion of autologous bone marrow mesenchymal stem cells for treatment of stroke in 30 cases

背景:自体骨髓间充质干细胞对神经功能缺损的修复有一定的作用,但对脑卒中的治疗作用尚缺乏较为严格的对照研究。目的:观察自体骨髓间充质干细胞回输治疗脑卒中患者的临床效果。方法:对30例要求进行自体骨髓间充质干细胞回输治疗的脑卒中住院患者予以自体骨髓间充质干细胞回输治疗,同时期30例未接受干细胞治疗的脑卒中住院患者作为对照组。用《临床神经功能缺损程度评分量表》评分作为疗效评估指标,观察治疗后6个月两组的神经功能恢复情况及其差异,并观察其安全性。结果及结论:治疗后6个月时两组《临床神经功能缺损程度评分量表》分值均下降,自身对照差异有显著性意义(P<0.05):干细胞治疗组分值下降更多,与对照组下降分值比较,差异有显著性意义(P<0.05)。提示自体骨髓间充质干细胞移植治疗脑血管病有确切效果并且安全。但有待于扩大样本量,并且严格随机、双盲、对照的临床观察进一步证实。

BACKGROUND：Autologous bone marrow mesenchymal stem cells have certain effects on repairing the neurologic impairment, but there are no well-controlled studies describing autologous bone marrow mesenchymal stem cells for treatment of stroke.OBJECTIVE：To observe the clinical effects of autologous bone marrow mesenchymal stem cell reinfusion for treatment of stroke.METHODS：Thirty stroke patients treated by autologous bone marrow mesenchymal stem cells reinfusion were included in the experimental group. Thirty stroke patients who did not receive autologous bone marrow mesenchymal stem cell reinfusion were included in the control group. The National Institutes of Health Stroke Scale （NIHSS） was used to assess the clinical efficacy. At 6 months after treatment, the neurological function recovery and the safety of autologous bone marrow mesenchymal stem cells were investigated.RESULTS AND CONCLUSION： The NIHSS score decreased significantly in the two groups after 6 months of treatment （P 0.05）. There was significant difference in NIHSS score between before and after treatment （P 0.05）. The NIHSS score of the control group decreased significantly than that of the experimental group （P 0.05）. Autologous bone marrow mesenchymal stem cell reinfusion for treatment of cerebrovascular disease is effective and safe. But this needs to be further confirmed by strictly randomized, double-blinded, controlled clinical studies involving a larger number of samples.